Erstes Quartal mit Wachstum von 2% in Schweizer Franken; 7%[1] zu konstanten Wechselkursen

NEXT STORY
Novartis Kymriah® receives FDA Regenerative Medicine Advanced Therapy designation in follicular lymphoma
PREV STORY
Medtronic Provides Update on COVID-19 Pandemic Response and Impact
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Fortress Biotech Announces Virtual Two-Day Corporate Access Summit Hosted by B. Riley FBR on Tuesday, August 18 and Wednesday, August 19, 2020

author_avatar
NASDAQ Market News

Rubius Therapeutics to Host Virtual Preclinical Pipeline and Platform Technology Day on December 16, 2021

author_avatar
NASDAQ Market News

Positive Results of Clinical Trial Comparing Coherus’ Ranibizumab Biosimilar Candidate CHS-201 to Reference Product Lucentis® (Ranibizumab) in the Treatment of Neovascular (Wet) Age-Related Macular Degeneration (nAMD) Presented at Retina Society Annual Scientific Meeting

author_avatar
NASDAQ Market News